Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus

Pathogens and Global Health

Volumn 106, Issue 1, 2012, Pages 12-19

  Ammendolia, Maria Grazia ^a   Agamennone, Mariangela ^b   Pietrantoni, Agostina ^a   Lannutti, Fabio ^b   Siciliano, Rosa Anna ^c   de Giulio, Beatrice ^c   Amici, Carla ^d   Superti, Fabiana ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antiviral; Bovine lactoferrin; C lobe; Influenza; Peptides

Indexed keywords

ANTIVIRUS AGENT; BOVINE LACTOFERRIN; LACTOFERRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COW; CYTOTOXICITY TEST; FAR WESTERN BLOTTING; HEMAGGLUTINATION; HEMAGGLUTINATION INHIBITION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MOLECULAR DOCKING; NONHUMAN; SEQUENCE ANALYSIS; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; DOGS; DRUG EVALUATION, PRECLINICAL; HEMAGGLUTININS; LACTOFERRIN; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE; PEPTIDE FRAGMENTS; PROTEIN BINDING; SEQUENCE ALIGNMENT;

EID: 84864067034     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773212Y.0000000004     Document Type: Article

References (50)

1. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982:307:580-4.
2. Palese P, Shaw ML, Knipe DM, Howley PM (editors). Orthomyxoviridae: the viruses and their replication. In: Fields virology. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
3. Belshe RB, Burk B, Newman F, Cerruti RL, Sim IS. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis. 1989:159:430-5.
4. Hayden FG. Antiviral resistance in influenza viruses-implications for management and pandemic response. N Engl J Med. 2006:354:785-8.
5. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-65.
6. Meijer A, Lackenby A, Hungnes O, Lina B, van der Werf S, Schweiger B, et al. European influenza surveillance scheme Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis. 2009;15:552-60.
7. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, Marshall SA, et al. Infections with oseltamivirresistant influenza A(H1N1) virus in the United States. JAMA 2009;30:1034-41.
8. Wilson IA, Skehel JJ, Wiley DC. Structure of the hemagglutinin membrane glycoprotein of influenza virus at 3 A° resolution. Nature. 1981;289:366-73.
9. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000;69:531-69.
10. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem. 1987;56:365-94.
11. May JT. Microbial contaminants and antimicrobial properties of human milk. Microbiol Sci. 1988;5:42-6.
12. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica. 1995;80:252-67.
13. Palma C, Cassone A, Serbousek D, Pearson CA, Djeu JY. Lactoferrin release and interleukin-1, interleukin-6, and tumor necrosis factor production by human polymorphonuclear cells stimulated by various lipopolysaccharides: relationship to growth inhibition of Candida albicans. Infect Immun. 1992;60:4604-11.
14. Harmsen MC, Swart PJ, de B'ethune MP, Pawels R, De Clercq E, Th'e TH, et al. Antiviral effects of plasma and milk proteins: lactoferrin shows a potent activity against both human immunodeficiencyvirus and human cytomegalovirus replication in vitro. J Infect Dis. 1995;172:380-8.
15. Beljaars L, van der Strate BW, Bakker HI, Reker-Smit C, van Loenen-Weemaes AM, Wiegmans FC, et al. Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. Antivir Res. 2004;63:197-208.
16. Hasegawa K, Motsuchi W, Tanaka S, Dosako S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn J Med Sci Biol. 1994;47:73-85.
17. Marchetti M, Trybala E, Superti F, Johansson M, Bergström T. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology. 2004;18:405-13.
18. Marchetti M, Ammendolia MG, Superti F. Glycosaminoglycans are not indispensable for the anti-herpes simplex virus type 2 activity of lactoferrin. Biochimie. 2009;91:155-9.
19. Ammendolia MG, Marchetti M, Superti F. Bovine lactoferrin prevents the entry and intercellular spread of herpes simplex virus type 1 in Green Monkey Kidney cells. Antiviral Res. 2007;76:252-62.
20. Yi M, Kaneko S, Yu DY, Murakami S. Hepatitis C virus envelope proteins bind lactoferrin. J Virol. 1997;71:5997-6002.
21. Murphy ME, Kariwa H, Mizutani T, Yoshimatsu K, Arikawa J, Takashima I. In vitro antiviral activity of lactoferrin and ribavirin upon hantavirus. Arch Virol. 2000;145:1571-82.
22. Hara K, Ikeda M, Saito S, Matsumoto S, Numata K, Kato N, et al. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res. 2002;24:228-35.
23. Sano H, Nagai K, Tsutsumi H, Kuroki Y. Lactoferrin and surfactant protein A exhibit distinct binding specificity to F protein and differently modulate respiratory syncytial virus infection. Eur J Immunol. 2003;33:2894-902.
24. Norris GE, Gartner AL, Anderson BF, Ward J, Baker EN, Rumball SV, et al. Preliminary crystallographic studies on bovine lactoferrin. J Mol Biol. 1986;191:143-5.
25. Moore SA, Anderson BF, Groom CR, Haridas M, Baker EN. Three-dimensional structure of diferric bovine lactoferrin at 2.8 uA resolution. J Mol Biol. 1997;274:222-36.
26. Superti F, Ammendolia MG, Valenti P, Seganti L. Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med Microbiol Immunol. 1997;186:83-91.
27. Pietrantoni A, Di Biase AM, Tinari A, Marchetti M, Valenti P, Seganti L, et al. Bovine lactoferrin inhibits adenovirus infection by interacting with viral structural polypeptides. Antimicrob Agents Chemother. 2003;47:2688-91.
28. Ammendolia MG, Pietrantoni A, Tinari A, Valenti P, Superti F. Bovine lactoferrin inhibits echovirus endocytic pathway by interacting with viral structural polypeptides. Antiviral Res. 2007;73:151-60.
29. Pietrantoni A, Dofrelli E, Tinari A, Ammendolia MG, Puzelli S, Fabiani C, et al. Bovine lactoferrin inhibits influenza A virus induced programmed cell death in vitro. Biometals. 2010;23:465-75.
30. Gaush CR, Smith TF. Replication and plaque assay of influenza virus in an established line of canine kidney cells. Appl Microbiol. 1968;16:588-94.
31. Rimmelzwaan GF, Baars M, Claas EC, Osterhaus AD. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods. 1998;74:57-66.
32. Pietrantoni A, Ammendolia MG, Tinari A, Siciliano R, Valenti P, Superti F. Bovine lactoferrin peptidic fragments involved in inhibition of Echovirus 6 in vitro infection. Antiviral Res. 2006:69:98-106.
33. Superti F, Siciliano R, Rega B, Giansanti F, Valenti P, Antonini G. Involvement of bovine lactoferrin metal saturation, sialic acid and protein fragments in the inhibition of rotavirus infection. Biochim Biophys Acta. 2001;1528:107-15.
34. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-5.
35. Morris GM, Goodsell DS, Halliday RS, Huey R, William E, Hart WE, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998;19:1639-62.
36. Chen R, Weng Z. Docking unbound proteins using shape complementarity, desolvation, and electrostatics. Proteins. 2002;47:281-94.
37. Li L, Chen R, Weng Z. RDOCK: refinement of rigid-body protein docking predictions. Proteins. 2003;53:693-707.
38. Kozakov D, Brenke R, Comeau SR, Vajda S. PIPER: an FFTbased protein docking program with pairwise potentials. Proteins. 2006;65:392-406.
39. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res. 2005;33:W363-7.
40. Andrusier N, Nussinov R, Wolfson HJ. FireDock: fast interaction refinement in molecular docking. Proteins. 2007;69:139-59.
41. Mashiach E, Schneidman-Duhovny D, Andrusier N, Nussinov R, Wolfson HJ. FireDock: a web server for fast interaction refinement in molecular docking. Nucleic Acids Res. 2008;36:W229-32.
42. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324:246-51.
43. Kasowski EJ, Garten RJ, Bridges CB. Influenza pandemic epidemiologic and virologic diversity: reminding ourselves of the possibilities. Clin Infect Dis. 2011;52(Suppl 1):S44-9.
44. Russell RJ, Gamblin SJ, Haire LF, Stevens DJ, Xiao B, Ha Y, et al. H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes. Virology. 2004;325:287-96.
45. Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem. 2010;285:28403-9.
46. Huang Q, Opitz R, Knapp EW, Herrmann A. Protonation and stability of the globular domain of influenza virus hemagglutinin. Biophys J. 2002;82:1050-8.
47. Mancini N, Solforosi L, Clementi N, DeMarco D, Clementi M, Burioni R. A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral Res. 2011;92:15-26.
48. Edwards MJ, Dimmock NJ. Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J Virol. 2001;75:10208-18.
49. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009;16:265-73.
50. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333:850-6.